Scientific ReportsBiophysicsPeer-reviewed journal article
Structure-based discovery of inhibitors of Mac1 domain of nonstructural protein-3 of SARS-CoV-2 by machine learning-augmented screening of chemical space
Fuqiang BaniD, Rahul Ravichandran, G.J. CorreyiD, Oleksandra HerasymenkoiD, Madhushika SilvaiD, Suzanne Z. AcklooiD, Albina Bolotokova, Irene ChauiD, Elisa GibsoniD, Rachel HardingiD, Ashley HutchinsoniD, P. LoppnauiD, James S. FraseriD, Matthieu SchapiraiD, Artem R CherkasoviD, Francesco GentileiD
Abstract
Significant efforts have been recently dedicated to the discovery of small molecule inhibitors against the Macrodomain 1 (Mac1) of nonstructural protein 3 (NSP3) as potential antivirals for SARS-CoV-2. Thus, Mac1 has also been selected as the target for the Critical Assessment of Hit-finding Experiments (CACHE) challenge #3. As contestants in that challenge, we developed a computational strategy that ranked on the top among all 23 participants in the competition and resulted in the discovery of a novel chemical series of non-charged Mac1 inhibitors. Those have been identified through the combination of machine learning-accelerated virtual screening of Enamine REAL Diversity Subset of approximately 25 million compounds and consequent hit expansion into the entire Enamine REAL Space library. In particular, the initially identified hit compound CACHE3-HI_1706_56 (KD = 20 {micro}M) was explored by probing 17 close analogues from a library of 44 billion molecules from the Enamine REAL. All those analogues effectively displaced the Mac1-binding ADP-ribose peptide, and 12 were confirmed to engage with Mac1 by the Surface Plasmon Resonance experiments, revealing a new chemical series of compounds for hit-to-lead optimization. The structure of the CACHE3-HI_1706_56-Mac1 complex was further determined at high resolution with crystallography, confirming initial computational predictions. Our results illustrate the effectiveness of ML-accelerated docking to rapidly identify novel chemical series and provide a strong foundation for the development of SARS-CoV-2 NSP3 Mac1 inhibitors.
- Citations
- 2
- FWCI
- 7.18
- Field percentile
- top 5%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2
S. Gahbauer, G. J. Correy, … J. S. Fraser·bioRxiv·Jun 27, 2022
- Discovery of Drug-like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3
R. S. Virdi, R. V. Bavisotto, … D. Frick·bioRxiv·Jul 6, 2020
- Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking
M. Schuller, G. J. Correy, … Smi·bioRxiv·Nov 24, 2020
- Design, Synthesis and Evaluation of Inhibitors of the SARS-CoV-2 nsp3 Macrodomain
L. M. Sherrill, E. E. Joya, … D. V. Ferraris·bioRxiv·Feb 27, 2022
- Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning
G. J. Correy, Moira M. Rachman, … James S. Fraser·Science AdvancesPeer-reviewed·May 28, 2025
- Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening
A. Roy, Y. M. Alhammad, … A. R. Fehr·bioRxiv·Mar 1, 2022